Literature DB >> 25621162

Sickle erythrocytes and platelets augment lung leukotriene synthesis with downregulation of anti-inflammatory proteins: relevance in the pathology of the acute chest syndrome.

Michael Opene1, Joseph Kurantsin-Mills2, Sumair Husain1, Basil O Ibe1.   

Abstract

Initiation, progression, and resolution of vaso-occlusive pain episodes in sickle cell disease (SCD) have been recognized as reperfusion injury, which provokes an inflammatory response in the pulmonary circulation. Some 5-lipoxygenase (5-lox) metabolites are potent vasoconstrictors in the pulmonary circulation. We studied stimulation of production of the inflammatory eicosanoids leukotrienes (LTs) and prostaglandin E2 (PGE2) by isolated rat lungs perfused with sickle (HbSS) erythrocytes. Our hypothesis is that HbSS erythrocytes produce more LTs than normal (HbAA) erythrocytes, which can induce vaso-occlusive episodes in SCD patients. Lung perfusates were collected at specific time points and purified by high-pressure liquid chromatography, and LTC4 and PGE2 contents were measured by enzyme-linked immunosorbent assay (ELISA). Rat lung explants were also cultured with purified HbAA and HbSS peptides, and 5-lox, cyclooxygenase 1/2, and platelet-activating factor receptor (PAFR) proteins were measured by Western blotting, while prostacyclin and LTs produced by cultured lung explants were measured by ELISA. Lung weight gain and blood gas data were not different among the groups. HbSS-perfused lungs produced more LTC4 and PGE2 than HbAA-perfused lungs: 10.40 ± 0.62 versus 0.92 ± 0.2 ng/g dry lung weight (mean ± SEM; P = 0.0001) for LTC4. Inclusion of autologous platelets (platelet-rich plasma) elevated LTC4 production to 12.6 ± 0.96 and 7 ± 0.60 ng/g dry lung weight in HbSS and HbAA perfusates, respectively. HbSS lungs also expressed more 5-lox and PAFR. The data suggest that HbSS erythrocytes and activated platelets in patient's pulmonary microcirculation will enhance the synthesis and release of the proinflammatory mediators LTC4 and PGE2, both of which may contribute to onset of the acute chest syndrome in SCD.

Entities:  

Keywords:  5-lipoxygenase; PAF receptor; cyclooxygenase; leukotriene receptors; prostaglandins; pulmonary circulation

Year:  2014        PMID: 25621162      PMCID: PMC4278608          DOI: 10.1086/677363

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  47 in total

1.  Cardiovascular effects of common analgesics.

Authors:  H T Ong; L M Ong; T E Tan; K Y Chean
Journal:  Med J Malaysia       Date:  2013-04

2.  Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure.

Authors:  D Powars; J A Weidman; T Odom-Maryon; J C Niland; C Johnson
Journal:  Medicine (Baltimore)       Date:  1988-01       Impact factor: 1.889

Review 3.  Species variations in the pulmonary responses to arachidonic acid metabolites.

Authors:  N F Voelkel
Journal:  Prostaglandins       Date:  1985-05

4.  Microvascular hemodynamics in the sickle red blood cell perfused isolated rat lung.

Authors:  J Haynes; A E Taylor; D Dixon; N Voelkel
Journal:  Am J Physiol       Date:  1993-02

5.  Plasma and urinary leukotrienes in sickle cell disease: possible role in the inflammatory process.

Authors:  B O Ibe; J Kurantsin-Mills; J U Raj; L S Lessin
Journal:  Eur J Clin Invest       Date:  1994-01       Impact factor: 4.686

6.  Patterns of mortality in sickle cell disease in the United Kingdom.

Authors:  A Gray; E N Anionwu; S C Davies; M Brozovic
Journal:  J Clin Pathol       Date:  1991-06       Impact factor: 3.411

7.  Chronic pulmonary disorders in sickle cell disease: findings at thin-section CT.

Authors:  S L Aquino; G Gamsu; J V Fahy; S Claster; S H Embury; W C Mentzer; E P Vichinsky
Journal:  Radiology       Date:  1994-12       Impact factor: 11.105

Review 8.  Sickle red cell-endothelium interactions.

Authors:  Dhananjay K Kaul; Eileen Finnegan; Gilda A Barabino
Journal:  Microcirculation       Date:  2009-01       Impact factor: 2.628

Review 9.  Asthma in sickle cell disease.

Authors:  Manisha Newaskar; Karen A Hardy; Claudia R Morris
Journal:  ScientificWorldJournal       Date:  2011-05-26

10.  Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart disease.

Authors:  Elena Nobili; M Dolores Salvado; Lasse Folkersen; Laura Castiglioni; Jens Kastrup; Anders Wetterholm; Elena Tremoli; Göran K Hansson; Luigi Sironi; Jesper Z Haeggström; Anders Gabrielsen
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

View more
  2 in total

Review 1.  Inflammatory targets of therapy in sickle cell disease.

Authors:  Amma Owusu-Ansah; Chibueze A Ihunnah; Aisha L Walker; Solomon F Ofori-Acquah
Journal:  Transl Res       Date:  2015-07-11       Impact factor: 7.012

2.  Hypoxia-mediated impaired erythrocyte Lands' Cycle is pathogenic for sickle cell disease.

Authors:  Hongyu Wu; Mikhail Bogdanov; Yujin Zhang; Kaiqi Sun; Shushan Zhao; Anren Song; Renna Luo; Nicholas F Parchim; Hong Liu; Aji Huang; Morayo G Adebiyi; Jianping Jin; Danny C Alexander; Michael V Milburn; Modupe Idowu; Harinder S Juneja; Rodney E Kellems; William Dowhan; Yang Xia
Journal:  Sci Rep       Date:  2016-07-20       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.